Guidelines for diagnosis, treatment, and follow-up of bladder cancer: The influence of prognostic factors and the significance of random biopsies

Urologic Oncology

Volumn 4, Issue 4-5, 1998, Pages 94-105

  Lobel, B ^a   Abbou, C C ^b   Brausi, M A ^c   Flanigan, R C ^d   Kameyama, S ^e   Orikasa, S ^f   MacCaffrey, J ^g   Tachibana, M ^h  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

BLADDER BIOPSY; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CONFERENCE PAPER; CYSTECTOMY; EARLY DIAGNOSIS; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; URINARY TRACT CANCER;

EID: 0345104212     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(99)00019-8     Document Type: Conference Paper

References (89)

1. [1] Waters WB. Invasive bladder cancer - Where do we go from here? J Urol 1996;155:1910-1.
2. [2] Rischmann P, Bittard H, Bouchot O, et al. Protocole du sous-comité des tumeurs superficielles de la vessie. Etude de la cohorte: resultats et efficacité d'un cycle d'instillation endovésicale de BCG dans les tumeurs urothéliales pT1G3 après résection transuréthrale complète. Dans: Abbou CC, Lobel B, editeurs. Progrès en Urologie. Paris: Comité de Cancérologie de l'Association Française d'Urologie, 1996. pp. 42-8.
3. [3] Mansson A. The patient with bladder cancer. Thesis. Lund University, Sweden, 1997.
4. [4] Billerey C, Boccon-Gibod L, et al. Etude des variations inter pathologistes dans l'évaluation du grade et du stade des tumeurs vésicales. Dans: Abbou CC, Lobel B, editeurs. Progrès en Urologie. Paris: Comité de Cancérologie de l'Association Française d'Urologie, 1996. pp. 49-57.
5. [5] Walther PH. "Wildcatting" for breakthroughs in urothelial cancer detection and management. A frustrating business. Editorial. J Urol 1995;154:1348-50.
6. [6] Greven KM, Spera JA, Solin LJ, Morgan T, Hanks GE. Local recurrence after cystectomy alone for bladder carcinoma. Cancer 1992;69:2767-70.
7. [7] Hermanek P, Sabin LH. Classification of Malignant Tumours (4th edition). Berlin: Springer Verlag, 1992.
8. [8] Skinner DG, Lieskovsky G. Management of invasive and high-grade bladder cancer. In Skinner DG, Lieskovsky G, editors. Diagnosis and Management of Geniturinary Cancer. Philadelphia: WB Saunders, 1988. pp. 295-312.
9. [9] Soloway MS. The management of superficial bladder cancer. Cancer 1980;45:1856-65.
10. [10] Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta PF, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8.
11. [11] Sharkey FE, Sarosdy MF. The significance of central pathology review in clinical studies of transitional cell carcinoma in situ. J Urol 1997;157:68-71.
12. [12] Bouffioux CH, Kurth KH, Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organzation for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 1995;153:934-41.
13. [13] Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
14. [14] Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin N Am 1992;19:429-33.
15. [15] Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 1986;135:920-2.
16. [16] Prout GR, Barton BA, Griffin P, et al. Treated history of non-invasive grade one transitional cell carcinoma. J Urol, in press Urol Clin N Am 193:433.
17. [17] Raitanen MP, Nieminen P, Tammela TLJ. Impact of tumour grade, stage, number and size, and smoking and sex, on survival in patients with transitional cell carcinoma of the bladder. Br J Urol 1995;76:470-4.
18. [18] Chinegwundoh FI, Kaisary AV. Polymorphism and smoking in bladder carcinogenesis. Br J Urol 1996;77:672-5.
19. [19] Guillford MC, Petruckevitch A, Burney PGJ, et al. Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment. Br Med J 1991;303:437-40.
20. [20] Mansson A, Anderson H, Collen S. Time lag to diagnosis of bladder cancer - influence of psychosocial parameters and level of healthcare provision. Scand J Urol Nephrol 1993;27:363-5.
21. [21] Sultana SR, Goodman CM, Byrne DJ, et al. Microscopic haematuria: urological investigation using a standard protocol. Br J Urol 1996;78: 691-8.
22. [22] Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol Clin N Am 1992;19:455-65.
23. [23] Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1994;130:1278-85.
24. [24] Guidelines for the Cancer Related Checkup: Recommendations and Rationale. New York: American Cancer Society, 1981.
25. [25] Mohr DN, Offord KP, Owen RA, Melton LJ 3rd. Asymptomatic microhematuria and urologic disease: a population-based study. JAMA 1986;256:224-9.
26. [26] Hendry WF, Manning N, Perry NM, et al. The effects of haematuria service on the early diagnosis of bladder cancer. In: Oliver RTD, Hendry WF, Bloom HJG, editors. Bladder Cancer: Principles of Combination Therapy. London: Butterworths, 1981. pp. 19-25.
27. [27] Wallace DMA, Hindmarsh JR, Webb, JN, et al. The role of multiple biopsies in the management of patients with bladder cancer. Br J Urol 1979;51:535-40.
28. [28] Strabanek P, Walsh A, editors. Bladder Cancer. UICC Technical Report Series Workshop on the Biology of Human Cancer. 60(13). Geneva: UICC.
29. [29] Hillman BJ, Silvert M, Cook G, et al. Recognition of bladder tumors by excretory urography. Radiology 1981;138:319-23.
30. [30] McFarlane JP, Ellis BW, Harland SJ. The management of superficial bladder cancer: an interactive seminar. Br J Urol 1996;78:372-8.
31. [31] Goessi C, Knispel HH, Miller K, Klan R. Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol 1997;157: 480-1.
32. [32] Badalament RA. More is simply more and not necessarily better. J Urol 1996;156:61-2.
33. [33] Kiemeney LA, Witjes LA, Heijbroek RP, Debruyne FM, Verbeek AL. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer 1994;30A: 1621-5.
34. [34] Mufti GR, Singh M. Value of random mucosal biopsies in the management of superficial bladder cancer. Eur Urol 1992;22:288-93.
35. [35] Kiemeney LA, Witjes JA, Heijbroek RP, Koper NP, Verbeek AL, Debruyne FM. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-operative Urological Group. Br J Urol 1994;73:164-71.
36. [36] Chopin DK, et al. Facteurs pronostiques des tumeurs superficielles de vessie. Progrès en Urologie 1993;(Suppl.):142-7.
37. [37] Farrow GM, Utz DC, Rife CC, Greene LF. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res 1977;37:2794-8.
38. [38] Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin N Am 1992;19:435-53.
39. [39] Gregoire M, Fradet Y, Meyer F, et al. Diagnostic accuracy of urinary cytology and deoxyribonucleic acid flow cytometry and cytology on bladder washings during follow up for bladder tumors. J Urol 1997; 157:1660-4.
40. [40] Yaman O, Baltaci S, Arikan N, Yilmaz E, Gogus O. Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. Br J Urol 1996;78:197-200.
41. [41] Braendengen M, Winderen M, Fossa SD. Clinical significance of routine pre-cystectomy bone scans in patients with muscle-invasive bladder cancer. Br J Urol 1996;77:36-40.
42. [42] Koraitim M, Kamal B, Metwalli N, Zaky Y. Transurethral ultrasonographic assessment of bladder carcinoma: its value and limitation. J Urol 1995;154:375-8.
43. [43] Pycha A, Mian C, Haitel A, Hofbauer J, Wiener H, Marberger M. Fluorescence in situ hybridization identifies more aggressive types of primary noninvasive (stage pTa) bladder cancer. J Urol 1997;157:2116-9.
44. [44] Underwood MA, Reeves J, Smith J, et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol 1996;77:659-66.
45. [45] Sarosdy MF, deVere White RW, et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995;154:379-84.
46. [46] Malkowicz SB. Superficial bladder cancer - incremental insight. J Urol 1996;155:488-9.
47. [47] Hudson A. New intravesical agents for superficial bladder cancer. Adv Urol 1997;10:349-71.
48. [48] Herr HW, Laudone VP, Badalament RA, et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988;6:1450-5.
49. [49] Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996;156:1934-41.
50. [50] Schulman CC, Robinson M, Denis L, et al. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Eur Urol 1982;8:207-12.
51. [51] Tolley DA, Hargreave TB, Smith PH. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J 1988;296:1759-61.
52. [52] Brosman SA. BCG in the management of superficial bladder cancer. Urology 1984;23:82-7.
53. [53] Lamm DL, Crawford ED, Blumenstein B, et al. Maintenance BCG immunotherapy of superficial bladder cancer; a randomized prospective Southwest oncology group study. J Urol 1997;157:831.
54. [54] Grunwald IE, Stein A, Rashcovitsky R, Shifroni G, Lurie A. A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer. J Urol 1997;157: 487-91.
55. [55] Lamm DL, Sarosdy MF, Grossman HB, et al. Maintenance vs. nonmaintenance BCG immunotherapy of superficial bladder cancer: a Southwest Oncology Group Study. J Urol 1990;143:341A.
56. [56] de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer:proceding, stability and prognostic value. J Urol 1996;155:477-82.
57. [57] Cant JD, Murphy WM, Soloway MS. Prognostic significance of urine cytology on initial follow-up after intravesical mitomycin C for superficial bladder cancer. Cancer 1986;57:2119-22.
58. [58] Milani C, Bassi P, Menighini A, et al. Mitomycin C in multiple superficial bladder tumors: short-term therapy, long-term results. Urol Int 1992;48:154-6.
59. [59] Lamm DL. Carcinoma in situ. Urol Clin N Am 1992;19:499-508.
60. [60] Mhidia A, Ferrer P, Lobel B, et al. Pharmacokinetics of plasma mitomycin C (MMC) when instilled immediately following transurethral resection for bladder tumor. [Abstract] J Urol 1997;150:50.
61. [61] Tannock IF. The current status of adjuvant chemotherapy for bladder cancer. Semin Urol 1990;8:291-7.
62. [62] Badalament RA, Ortolano V, Burgers JK. Recurrent or aggressive bladder cancer. Indications for adjuvant intravesical therapy. Urol Clin N Am 1992;19:485-98.
63. [63] Droller MJ. Treatment of regionally advanced bladder cancer. An overview. Urol Clin N Am 1992;19:685-93.
64. [64] Whitmore WF Jr, Batata MA, Ghonheim MA, Grabstald H, Unal A. Radical cystectomy with or without irradiation in the treatment of bladder cancer. J Urol 1977;118:184-7.
65. [65] Lerner SP, Skinner E, Skinner DG, et al. Radical cystectomy in regionally advanced bladder cancer. Urol Clin N Am 1992;19:713-23.
66. [66] Lerner SP, Skinner DG, Lieskovsky G, et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol 1992;147:402A.
67. [67] Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 1982;128:34.
68. [68] Wishnow KI, Johnson DE, Ro JY, Swanson DA, Babaian RJ, von Eschenbach AC. Incidence, extent and location of unsuspected pelvic lymph node metastases in patients undergoing radical cystectomy for bladder cancer. J Urol 1987;137:408-10.
69. [69] Martins FE, Bennet CJ, Skinner DG. Options in replacement cystoplasty following radical cystectomy: high hopes or successful reality. J Urol 1995;153:1363-72.
70. [70] Lerner SP, Hayani A, O'Hallaren P., et al. The role of surgery in the management of pediatric pelvic rhabdomyosarcoma. J Urol 1995;154: 540-5.
71. [71] Rowland RG. Indications and contraindications for continent urinary diversion. Scand J Urol Nephrol 1992;142(suppl.):57.
72. [72] Koiso K, Shipley W, Keuppens F, et al. The status of bladder-preserving therapeutic strategies in the management of patients with muscle-invasive bladder cancer. Int J Urol 1995;2(suppl.):49-57.
73. [73] Gospodarowicz MK, Quilty PM, Scalliet P, et al. The place of radiation therapy as definitive treatment of bladder cancer. Int J Urol 1995; 2:41-8.
74. [74] Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N. Primary cysplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors. J Urol 1996;155:1897-902.
75. [75] Fellin G, Graffer U, Bolner A, Ambrosinia G, Caffo O, Luciani L. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-instiution phase II study. Br J Urol 1997;80:44-9.
76. [76] Hulewicz G, Roy P, Coquard R, et al. La radiotherapie per-operatoire dans le traitement conservateur des cancers infiltrants de la vessie. Progrès en Urologie 1997;7:229-34.
77. [77] Montie JE, Whitmore WF, Grabstald HM, Yagoda A. Unresectable carcinoma of the bladder. Cancer 1983;51:2351-5.
78. [78] Steinberg GD, Trump DL, Cummings KB. Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin N Am 1992;19:735-46.
79. [79] Logothetis CJ, Johnson DE, Chong C, et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol 1998;6:1590.
80. [80] Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987;60: 574-85.
81. [81] Culp DA. Palliative treatment of the patient with disseminated carcinoma of the bladder. Semin Oncol 1979;6:249-53.
82. [82] Daehlin L, Ashken LA, Haukaas S. Squamous cell carcinoma of the urinary bladder. Scand J Urol Nephrol 1991;25:275-6.
83. [83] Sharfi AR, el Sir S, Beleil O. Squamous cell carcinoma of the urinary bladder. Br J Urol 1992;69:369-71.
84. [84] Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordonez NG. Adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;2165-72.
85. [85] Ashken H. The Working Group for the Investigation and Treatment of Urological Cancers in the United Kingdom. British Association of Urological Surgeons, 1996.
86. [86] Heaton ND, Kadow C, Pryor JP. Rhabdomyosarcoma of the bladder base in two older children. Br J Urol 1992;69:208-9.
87. [87] Rogers E, Scardino PT. A simple ileal substitute bladder after radical cystectomy: experience with a modification of the studer pouch. J Urol 1995;153:1432-8.
88. [88] Hautmann RE. Reconstruction and diversion. J Urol 1995;154:989.
89. [89] American Joint Committee on Cancer. Cancer Staging Manual, 5th edition. Philadelphia: Lippincott-Raven, 1997.